ACUITAS THERAPEUTICS
LIVE

Serial Number

97915885

Owner

Acuitas Therapeutics, Inc.

Attorney

Karen Won

Filing Date

May 1, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ACUITAS THERAPEUTICS Trademark

Serial Number: 97915885

ACUITAS THERAPEUTICS is a trademark filed by Acuitas Therapeutics, Inc. on May 1, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

Acuitas Therapeutics, Inc. (4 trademarks)

405-6190 Agronomy Road
Vancouver, B.C. V6T1Z3 , CA

Entity Type: 03

Trademark Details

Filing Date

May 1, 2023

Registration Date

Not Registered

Published for Opposition

July 21, 2026

Goods & Services

Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, and nucleic acid therapeutics as pharmaceutical preparations; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, vaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders and allergies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles.

Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders

Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles

Nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 21, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jul 21, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 15, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 24, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 16, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 16, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 16, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 12, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 12, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 12, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 15, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 8, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 8, 2026 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 27, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 27, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 27, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 22, 2026 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 16, 2026 RCSC
ASSIGNED TO EXAMINER
Jan 6, 2026 DOCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jul 15, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 16, 2025 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 17, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 17, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 17, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 17, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 17, 2024 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 18, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 18, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 18, 2024 COAR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 18, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 18, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jul 18, 2024 CNSL
EXAMINER'S AMENDMENT ENTERED
Jul 18, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 18, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 18, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 18, 2024 CNEA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 12, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
May 12, 2024 GNSL
SUSPENSION LETTER WRITTEN
May 12, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 16, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 26, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 26, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 26, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 26, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 30, 2023 NWOS
NEW APPLICATION ENTERED
May 4, 2023 NWAP